^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    misitatug blivedotin (RC88)

    i
    Other names: RC88, RC88-ADC, RC-88
    Associations

    News

    Trials
    Company:
    Rongchang Pharma
    Drug class:
    Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, RemeGen Co., Ltd. | Trial completion date: May 2024 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    4ms
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, RemeGen Co., Ltd. | N=51 --> 200
    Enrollment change • Metastases
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    5ms
    A Study of RC88 Combined With JS001 for Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=82, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023
    Enrollment open • Trial initiation date
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    5ms
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=81, Recruiting, RemeGen Co., Ltd. | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)
    5ms
    RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=88, Not yet recruiting, RemeGen Co., Ltd.
    New P2 trial
    |
    misitatug blivedotin (RC88)
    10ms
    Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88. (PubMed, Clin Transl Sci)
    TSC from mice and predicted human PK were integrated to predict human efficacy dose. Results showed that 2 cell lines were sensitive to drugs, and the predicted efficacy dose was between 0.82 and 1.96 mg/kg q1w.
    PK/PD data • Preclinical • Journal
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    1year
    A Study of RC88 Combined With JS001 for Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=82, Not yet recruiting, RemeGen Co., Ltd.
    New P1/2 trial • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    over1year
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=81, Recruiting, RemeGen Co., Ltd.
    New P1 trial
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)
    2years
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=51, Recruiting, RemeGen Co., Ltd. | Phase classification: P1 --> P1/2 | N=31 --> 51 | Trial completion date: May 2022 --> May 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)